sar-407899
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00914277)
Timeline
Indications
Mechanism of action
- Rho-associated protein kinaseINHIBITOR
Rho-associated protein kinase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]ccc2cc(OC3CCNCC3)ccc12- Mol. weight
- 244.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1667969 ↗
- ChEMBLCHEMBL3545341 ↗
Also known as
- sar407899
- sar407899
- sar-407899
- sar-407899
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03236311 | Phase 2 | Oct 12, 2017 | Sanofi |
| NCT01485900 | Phase 1 | Nov 1, 2011 | Sanofi |
| NCT00914277 | Phase 2 | May 1, 2009 | Sanofi, SGS Life Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 3 | 3 | 2 | 2009 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1